InsidersTradesSigma
Follow the Puma Biotechnology, INC. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Puma Biotechnology, INC. has recorded 198 insider filings. Market capitalisation: €436.7m. The latest transaction was reported on 8 July 2026 (Cession). Among the most active insiders: AUERBACH ALAN H. The full history is accessible without an account.
198
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€5m
137 ops.
Sell Volume
53Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 1,766 of 28,932 companies
77.6
score / 100
Value73
Quality83
FCF yld8.8%
Earn yld6.6%
EV/EBITDA9.4x
ROE22%
Gross mgn75%
Net mgn14%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 July 2026
Declarations198 total
44,058 shares@ US$8.2630.087% mcap8.3% of flowCommon StockSEC:0001437749-26-023079:0
8,460 shares@ US$8.2630.017% mcap21.9% of flowCommon StockSEC:0001437749-26-023078:0
9,386 shares@ US$8.2630.018% mcap17.9% of flowCommon StockSEC:0001437749-26-023077:0
44,058 shares@ US$8.26280.091% mcap7.8% of flowCommonSEC144:0001959173-26-005126
8,460 shares@ US$8.26280.018% mcap19.2% of flowCommonSEC144:0001959173-26-005123
9,386 shares@ US$8.26280.019% mcap15.6% of flowCommonSEC144:0001959173-26-005121
27,000 sharesCommon StockSEC:0001437749-26-020702:0
27,000 sharesCommon StockSEC:0001437749-26-020703:0
11,610 sharesCommon StockSEC:0001437749-26-020703:1
11,610 shares@ US$7.260.021% mcap42.0% of flowCommonSEC144:0001959173-26-004588
22,000 shares@ US$7.260.039% mcap21.8% of flowCommonSEC144:0001959173-26-004589
10,800 shares@ US$7.260.019% mcap11.7% of flowCommonSEC144:0001959173-26-004584
8,100 shares@ US$7.260.015% mcap29.8% of flowCommonSEC144:0001959173-26-004586
27,000 shares@ US$7.260.048% mcap19.6% of flowCommonSEC144:0001959173-26-004590
159,778 shares0Common StockSEC:0001437749-26-004948:0
49,394 shares0Common StockSEC:0001437749-26-004947:0
46,739 shares0Common StockSEC:0001437749-26-004946:0
16,938 shares@ US$5.8442.0% of flowCommon StockSEC:0001437749-26-000924:0
3,973 shares@ US$5.8445.9% of flowCommon StockSEC:0001437749-26-000922:0
4,540 shares@ US$5.8444.9% of flowCommon StockSEC:0001437749-26-000921:0
20,000 shares@ US$4.861420.0% of flowCommon StockSEC:0001437749-25-034874:0
27,000 shares@ US$3.367100.0% of flowCommon StockSEC:0001437749-25-023268:0
5,587 shares@ US$3.5334.6% of flowCommon StockSEC:0001437749-25-022551:0
4,374 shares@ US$3.5335.1% of flowCommon StockSEC:0001437749-25-022549:0
25,592 shares@ US$3.5332.1% of flowCommon StockSEC:0001437749-25-022547:0
25 of 198 declarations
关于 Puma Biotechnology, INC.
Puma Biotechnology, Inc. 是一家在美国上市的生物制药公司，在纳斯达克以股票代码 PBYI 交易。该公司总部位于美国加利福尼亚州洛杉矶，专注于获取、开发和商业化新型癌症疗法。其战略是作为一家专业的肿瘤生物技术公司，而非广泛多元化的制药集团：Puma 倾向于许可或引进具有临床先例的资产，通过开发推进它们，然后通过专注的执行来建立商业价值。该公司目前的法人形式可追溯到 2010 年，创始人 Alan H. Auerbach 自成立以来一直是业务的核心。（[pumabiotechnology.com](https://www.pumabiotechnology.com/about/overview.html?utm_source=openai)） Puma 的核心商业资产是 NERLYNX® (neratinib)，一种口服肿瘤疗法，仍然是公司主要的收入驱动因素。近期公司披露显示，产品收入绝大部分来自 NERLYNX 销售，辅以选定的国际安排的特许权使用费收入。除了维护 NERLYNX 特许经营权外，Puma 还通过 alisertib 增加了第二个增长支柱，这是一项于 2022 年从武田制药引进的资产。该药物目前正在 ALISCA™-Breast1 和 ALISCA™-Lung1 等临床项目中推进，这些项目针对未经化疗的 HER2 阴性、激素受体阳性转移性乳腺癌和广泛期小细胞肺癌。对于投资者来说，这是一个重要的点：Puma 仍然高度依赖一种上市产品，但它也在努力扩大其产品线并随着时间的推移减少单一资产集中度。（[investor.pumabiotechnology.com](https://investor.pumabiotechnology.com/news-releases/news-release-details/puma-biotechnology-reports-fourth-quarter-and-full-year-2025)） 从竞争角度来看，Puma 在靶向肿瘤学领域占据利基市场。NERLYNX 在 HER2 相关乳腺癌护理领域已确立地位，在该领域它在一个复杂但竞争激烈的治疗环境中竞争。Puma 不具备大型全球制药公司的规模；相反，其优势在于专业化、商业化的收入基础和严谨的资本配置。从地理上看，该业务仍主要以美国为中心，尽管该公司也受益于国际分许可和特许权使用费流，包括近期亚洲披露中提及的活动。（[investor.pumabiotechnology.com](https://investor.pumabiotechnology.com/news-releases/news-release-details/puma-biotechnology-reports-fourth-quarter-and-full-year-2025)） 近期里程碑具有建设性。Puma 报告的 2025 年业绩显示连续第三年盈利，总收入为 228.4 亿美元，并实现正经营现金流。管理层还指导 2026 年将继续盈利，并强调了未来 12 个月内 alisertib 的几项临床数据公布。对于关注美国医疗保健公司的国际投资者而言，PBYI 呈现出商业阶段的稳定性、产品集中风险以及与其肿瘤产品线相关的临床上行潜力。（[investor.pumabiotechnology.com](https://investor.pumabiotechnology.com/news-releases/news-release-details/puma-biotechnology-reports-fourth-quarter-and-full-year-2025)）
